Stockreport

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs [Yahoo! Finance]

Cocrystal Pharma, Inc.  (COCP) 
NASDAQ:AMEX Investor Relations: cocrystalpharma.com
PDF Topline data expected in 2024 from Phase 2a influenza A human challenge study and Phase 1 study with oral CDI-988, the first potential dual coronavirus-norovirus oral a [Read more]